- Home
- PHAR vs MNTK Comparison
PHAR vs MNTK Comparison
Compare PHAR & MNTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAR | MNTK |
|---|---|---|
| Founded | 1988 | 1980 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Natural Gas Distribution |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 231.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PHAR | MNTK |
|---|---|---|
| Price | $17.88 | $1.53 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $38.00 | $3.33 |
| AVG Volume (30 Days) | 27.2K | ★ 140.3K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $362,274,000.00 | $160,682,000.00 |
| Revenue This Year | $25.19 | $2.45 |
| Revenue Next Year | $4.47 | $15.31 |
| P/E Ratio | $3,085.37 | ★ N/A |
| Revenue Growth | ★ 26.78 | N/A |
| 52 Week Low | $7.50 | $1.53 |
| 52 Week High | $18.30 | $4.71 |
Technical Indicators
Market Signals| Indicator | PHAR | MNTK |
|---|---|---|
| Relative Strength Index (RSI) | 55.87 | 37.58 |
| Support Level | $16.55 | $1.63 |
| Resistance Level | $17.37 | $1.78 |
| Average True Range (ATR) | 0.67 | 0.12 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 72.25 | 13.04 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.